Status: Closed
Activation Date: 2000FEB14
Closing Date: 2003JAN03
Phase: III
Description: Phase III Study of Tomudex and Cisplatin versus Cisplatin in Malignant Pleural Mesothelioma
Eligibility: Histologically proven diagnosis of malignant mesothelioma of the pleura. Independent review of the pathology slides will be carried out on all patients.
Objective: To compare overall survival between the two treatment regimens in patients with malignant pleural mesothelioma. To determine toxicity, progression-free survival and Quality of Life. In the patient population with measurable disease, objective response to treatment and duration of response will be assessed.
Participation: Not limited
Lay Description: The purpose of this study is to compare the effects (good and bad) of cisplatin, a commonly used drug for this disease, to the combination of cisplatin and a new drug called tomudex.
Primary Publication Show
Other Publications Show
Inventory
Hide Tissue Samples
| Disease Site | Trial Code | Patients Accrued | Patients - Blocks | Patients - Slides | Patients - Blocks and/or Slides |
| LUNG | BR17 | 20 | 1 | 1 | 2 |
(Core size is 0.6 mm)
Hide
Fluid Samples| Disease Site | Trial Code | Patients Accrued | TMA Blocks | Patients on TMA Blocks |
| LUNG | BR17 | 20 | 0 | 0 |
| Disease Site | Trial Code | Patients Accrued | Patients - Whole Blood | Patients - Cellular Component of Blood | Patients - DNA extracted from Blood | Patients - RNA extracted from Blood | Patients - Plasma | Patients - Serum | Patients - Urine | Patients - Buccal |
| LUNG | BR17 | 20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |